Global Cinv Existing and Pipeline Drugs Market to Reach Us$1.88 Billion by 2020

Transparency Market

Research

CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic,

Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share,

Growth, Trends and Forecast 2014 - 2020

Published Date

29-Dec-2014

74 Page Report

Buy Now

Request Sample

Press Release

Global CINV Existing and Pipeline Drugs Market to Reach

US$1.88 billion by 2020:Transparency Market Research

Transparency Market Research

State Tower,

90, State Street, Suite 700.

Albany, NY 12207

United States

www.transparencymarketresearch.com

sales@transparencymarketresearch.com

CINV Existing And Pipeline Drugs

Market

REPORT DESCRIPTION

CINV Existing and Pipeline Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast

2014 - 2020

Chemotherapy induced nausea and vomiting (CINV) refers to the nausea and vomiting associated with cancer

chemotherapy. Various sources indicate that approximately 70% to 80% cancer patients undergoing chemotherapy exhibit

nausea and vomiting as major symptoms. Chemotherapy induced nausea and vomiting is an extremely debilitating

condition. Although there are currently a number of drugs available to manage CINV, they do not effectively address the

symptoms of this condition. The report on CINV existing and pipeline drugs market offers an insightful and in-depth

assessment of the current as well as future market potential of CINV drugs. Aloxi (palonosetron), Zofran generic

(ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC) are the major

currently available drugs extensively studied in the report. The historical market size and forecast for each of these drugs

(except for Akynzeo, as the U.S. Food and Drug Administration (FDA) approved it only in October 2014) in terms of

revenue (USD Million) has been provided in the report for the period from 2012 to 2020. In addition, the compounded

annual growth rate...